Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Johnson & Johnson has acquired Atraverse Medical, a medical devices business in the United States, for undisclosed terms. Johnson & Johnson acquisitions target Atraverse Medical’s HOTWIRE Transseptal Access System, an FDA-cleared RF guidewire and generator platform for next-generation left-heart access in cardiac ablation. The technology supports electrophysiologists performing left atrium access for atrial fibrillation and other cardiac arrhythmias, with reported use in about 3,000 clinical procedures. The healthcare M&A is an add on acquisition by a strategic buyer, expanding Johnson & Johnson’s MedTech cardiac ablation solutions. Johnson & Johnson expects the strategic acquisition to close in Q2 2026, subject to customary closing conditions.
Source
Read full article on insidermonkey.comvia GN - entered into definitive agreement · April 27, 2026
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026